Unaudited Consolidated Statements of Cash Flows
Three Months Ended | Years Ended | |||||||||||||||
(in $M) | December 31, 2020 | December 31, 2021 | December 31, 2020 | December 31, 2021 | ||||||||||||
Cash flows from operating activities: | ||||||||||||||||
Net income (loss) | $ (524 ) | $ 43 | $ (1,351 ) | $ (254 ) | ||||||||||||
Depreciation and amortization | 626 | 419 | 2,523 | 1,619 | ||||||||||||
Finance expense, net | 38 | 26 | 151 | 108 | ||||||||||||
Deferred income taxes | 14 | 40 | (38) | 93 | ||||||||||||
Other non-cash operating activities | (51) | (9) | (338) | 43 | ||||||||||||
Net change in working capital | 98 | 629 | 59 | 1,230 | ||||||||||||
Net cash provided by operating activities | 201 | 1,148 | 1,006 | 2,839 | ||||||||||||
Cash flows from investing activities: | ||||||||||||||||
Purchases of property, plant, equipment, and intangible assets | (203) | (649) | (592) | (1,766) | ||||||||||||
Other investing activities | 126 | 23 | 226 | 316 | ||||||||||||
Net cash used in investing activities | (77 ) | (626 ) | (366 ) | (1,450 ) | ||||||||||||
Cash flows from financing activities: | ||||||||||||||||
Proceeds from issuance of equity instruments | — | $1,444 | — | $1,444 | ||||||||||||
Repayments of shareholder loan | (137) | — | (487) | (568) | ||||||||||||
Repayment of debt, net | (248) | (72) | (556) | (343) | ||||||||||||
Other financing activities | 38 | 27 | 310 | 117 | ||||||||||||
Net cash provided by (used in) financing activities | (347 ) | 1,399 | (732 ) | 650 | ||||||||||||
Effect of exchange rate changes | 3 | (1) | 3 | (8) | ||||||||||||
Net change in cash and cash equivalents | (221 ) | 1,920 | (89 ) | 2,031 | ||||||||||||
Cash and cash equivalents at the beginning of the period | 1,129 | 1,019 | 997 | 908 | ||||||||||||
Cash and cash equivalents at the end of the period | $ 908 | $ 2,939 | $ 908 | $ 2,939 | ||||||||||||
Unaudited Reconciliation of IFRS to Adjusted Non-IFRS